Shenzhen Hepalink Pharmaceutical Group (09989) reported a net profit attributable to shareholders of RMB394 million for the first three quarters, down 28.84% year on year.
Shenzhen Hepalink Pharmaceutical Group (09989) announced its results for the first three quarters of 2026. The group recorded operating revenue of RMB3.797 billion, down 9.48% year on year; net profit attributable to shareholders of the listed company was RMB394 million, down 28.84% year on year; basic earnings per share were RMB0.2685.
Shenzhen Hepalink Pharmaceutical Group (09989) announced its results for the first three quarters of 2026. The Group recorded operating revenue of RMB3.797 billion, down 9.48% year on year; net profit attributable to shareholders of the listed company was RMB394 million, down 28.84% year on year; basic earnings per share were RMB0.2685.
Related Articles
SFQ GLOBAL (01953) completes placement of a total of 215 million placement shares, raising net proceeds of approximately HK$208 million
HUADIAN POWER (01071) reported a net profit attributable to shareholders of RMB3.908 billion for the first three quarters, down 39.29% year on year.
STANCHART (02888) repurchased 409,200 shares on October 28 for GBP8.5397 million.
SFQ GLOBAL (01953) completes placement of a total of 215 million placement shares, raising net proceeds of approximately HK$208 million
HUADIAN POWER (01071) reported a net profit attributable to shareholders of RMB3.908 billion for the first three quarters, down 39.29% year on year.
STANCHART (02888) repurchased 409,200 shares on October 28 for GBP8.5397 million.
